PharmacologyTier 1Medical Sciences concept

Opioid metabolite accumulation in renal impairment (morphine-6-glucuronide)

Core concept

Morphine metabolised hepatically to morphine-6-glucuronide (M6G, active, more potent than parent) and morphine-3-glucuronide (M3G, inactive analgesically, neuroexcitatory)
Both glucuronides renally cleared -> accumulate in renal impairment -> prolonged/exaggerated effect and toxicity
Applies broadly: many opioids have renally-cleared active or neurotoxic metabolites

Key detail

M6G accumulation -> exaggerated sedation, respiratory depression despite unchanged parent drug dose
M3G accumulation -> neuroexcitation: myoclonus, hyperalgesia, seizures -- not reversed by naloxone (M3G has negligible mu-opioid activity)
Pethidine (meperidine) metabolite norpethidine is proconvulsant and renally cleared -- pethidine relatively contraindicated in renal impairment

Clinical relevance

In renal impairment, prefer opioids with inactive or non-renally-cleared metabolites: fentanyl, buprenorphine, methadone (hepatic clearance dominant)
If morphine myoclonus occurs: reduce dose or rotate opioid, not just add benzodiazepine -- treat the cause
Myoclonus + hyperalgesia in a patient on morphine with rising creatinine suggests accumulation, not undertreated pain -- do not simply escalate the dose

Correlations

Same renal-accumulation principle applies to codeine (active metabolites) and tramadol (M1 metabolite, CYP2D6-dependent)
Opioid rotation in renal impairment overlaps with the OMEDD conversion note but the driver here is metabolite handling, not equianalgesic potency
Naloxone reverses mu-receptor-mediated toxicity (sedation, respiratory depression) but not M3G-driven myoclonus/hyperalgesia

3 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.

Get premium access